3
|
Prabhu JS, Patil S, Rajarajan S, Ce A, Nair M, Alexander A, Ramesh R, Bs S, Sridhar T. Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis. Ann Oncol 2021; 32. [PMID: 34220400 DOI: 10.1016/j.annonc.2021.03.052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background Glucocorticoid receptor (GR) is shown to have variable frequency of expression in invasive tumors of the breast. Investigation of additional nuclear receptors like GR in receptor negative tumors like triple negative breast cancer (TNBC) may have prognostic and therapeutic significance. Methods Expression of GR was evaluated by immunohistochemistry in 175 tumors of invasive breast cancer with long term follow up. GR Expression was separately evaluated in invasive tumor cells, stromal cells and tumor infiltrating lymphocytes (TIL's). Staining pattern was categorised as positive when more than 1% of the cells stained in each subpopulation of cells. Disease free survival was analysed between GR positive and negative status by Kaplan Meier analysis. Results Of the 175 tumors, 121 (70%) were ER positive, 53 (30%) were ER negative and 29% (51) were triple negative. 74% (130/175) tumors showed expression of GR in invasive tumor cells while (84%) 147/175 had expression in TIL's. No significant difference in distribution of GR was noted between ER positive and ER negative tumors (78% vs 66%, p-0.1). Of the TNBC's 54% (28/51) and 70% (36/51) showed expression of GR in invasive tumor and TIL's respectively. Overall, GR positive tumors had significant better survival than GR negative tumors (mean survival time of 85 vs 59 months respectively, p-0.04) Contrary to the reports that GR expression in TIL's are associated with immunosuppressive activity in model systems, TNBC's with increased expression of GR in immune cells were associated with better survival (Mean survival time 74 vs 41 months, log rank test- p-0.03). TNBC tumors which were GR negative had higher lymph node metastases (p-0.04) and none of the other clinical features like age, menopausal state, tumor size and grade were different between GR positive and negative tumors within TNBC. Conclusions Glucocorticoids (GC) are often used to alleviate the adverse symptoms during chemotherapy. Determining the GR status is of importance due to the pro cell survival effect of the glucocorticoids mediated through GR during chemotherapy. Though GC mediated effects on chemotherapy are controversial, our results indicate favourable effects in TNBC.
Collapse
Affiliation(s)
- J S Prabhu
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - S Patil
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - S Rajarajan
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - A Ce
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - M Nair
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - A Alexander
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| | - R Ramesh
- Department of Surgical Oncology, St Johns Medical College Hospital, Bangalore, India
| | - S Bs
- Department of Surgical Oncology, Shankara Cancer Hospital & Research Centre, Bangalore, India
| | - T Sridhar
- Molecular Medicine, St Johns Research Institute, Bangalore, India
| |
Collapse
|
6
|
Prabhu JS, Kaul R, Korlimarla A, Desai K, Gangadharan C, Rajarajan S, Nair MG, Alexander A, Kaluve R, Manjunath S, Correa M, Prasad MSN, Patil S, Srinath BS, Sridhar TS. Abstract P4-07-10: Epithelial mesenchymal transition associated with high miR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-07-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MicroRNA mediated molecular alterations are involved in the initiation and progression of cancer. Altered expression of multiple microRNAs is associated with endocrine resistance in hormone receptor positive HER2 negative (HR+/HER2-ve) cancer. The role of miR-221 in inducing epithelial to mesenchymal transition (EMT) is well documented especially in cell line model systems. However, the detailed mechanism of specific microRNAs in intrinsic and acquired resistance to endocrine therapy needs to be worked out. In addition, more needs to be done in the documentation of these mechanisms in human breast cancer specimens with complete clinical documentation and long-term follow-up. In this study, we have evaluated the clinical significance of miR-221 and its mechanistic role in EMT using human specimens and cell line models.
Materials and Methods: Formalin fixed paraffin embedded tumor from 129 HR+/HER2-ve breast cancer patients with a median follow up of 63 months were used for estimation of miR-221 by quantitative real time PCR. Expression levels of genes which are direct targets of miR-221 and related genes in EMT were analysed from these tumors. Survival between miR-221 high and low groups was compared by Kaplan Meier survival curves and prognostic relevance was estimated by Cox proportional hazard model.
Cell line experiments to investigate the role of miR-221 in inducing EMT through integrin β6 are underway in both wild type and tamoxifen resistant MCF-7 cell lines (A gift from Prof Ben Ho Park, Johns Hopkins University School of Medicine).
Results: A significant elevated level of miR-221 was observed in small proportion (14%) of HR+/HER2-ve tumors. miR-221 expression had an inverse correlation with both ER protein and ESR1 mRNA levels within HR+/HER2-ve tumors. Tumors with high levels of miR-221 showed significantly higher expression of integrin β6 which is a robust marker of EMT. Patients with high expression of miR-221 had a poorer survival in Kaplan Meier analysis.
Results of interrogation of EMT mediated through integrin related pathways involving miR-221 in cell line models will be presented.
Discussion: The association between miR-221 and integrin β6 in HR+/HER2-ve breast cancer with endocrine resistance suggests a potential link between an epigenetic regulator and a mediator of tumor-stromal interaction. The other mediators involved in this pathway are being investigated. miR-221 could be potentially used as a marker for identification of a poor prognostic subtype within HR+/HER2-ve breast cancers.
Citation Format: Prabhu JS, Kaul R, Korlimarla A, Desai K, Gangadharan C, Rajarajan S, Nair MG, Alexander A, Kaluve R, Manjunath S, Correa M, Prasad MSN, Patil S, Srinath BS, Sridhar TS. Epithelial mesenchymal transition associated with high miR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-07-10.
Collapse
Affiliation(s)
- JS Prabhu
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - R Kaul
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - A Korlimarla
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - K Desai
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - C Gangadharan
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - S Rajarajan
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - MG Nair
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - A Alexander
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - R Kaluve
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - S Manjunath
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - M Correa
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - MSN Prasad
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - S Patil
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - BS Srinath
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| | - TS Sridhar
- St Johns Research Institute, Bangalore, Karnataka, India; St Johns Medical College Hospital, Bangalore, Karnataka, India; St Johns Medical College, Bangalore, Karnataka, India; Shankara Cancer Hospital and Research Center, Bangalore, India
| |
Collapse
|